• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.

    11/14/25 4:27:07 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Upstream Bio, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    91678A107

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    91678A107


    1Names of Reporting Persons

    TCG Crossover GP I, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,117,103.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,117,103.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,117,103.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:   These securities are held of record by TCG Crossover I (as defined in item 2(a) below). TCG Crossover GP I (as defined in item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. The amount beneficially owned by each Reporting Person is determined based on 54,038,591 shares of Common Stock outstanding as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the Commission) on November 5, 2025 (the Form 10-Q).


    SCHEDULE 13G

    CUSIP No.
    91678A107


    1Names of Reporting Persons

    TCG Crossover Fund I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,117,103.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,117,103.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,117,103.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   These securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. The amount beneficially owned by each Reporting Person is determined based on 54,038,591 shares of Common Stock outstanding as reported in the Issuer's Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    91678A107


    1Names of Reporting Persons

    Chen Yu
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,117,103.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,117,103.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,117,103.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   These securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. The amount beneficially owned by each Reporting Person is determined based on 54,038,591 shares of Common Stock outstanding as reported in the Issuer's Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Upstream Bio, Inc.
    (b)Address of issuer's principal executive offices:

    890 Winter Street, Suite 200, Waltham, MA 02451
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 1 (Amendment No. 1) amends and supplements the Schedule 13G initially filed with the Commission on February 14, 2025 (the Original Schedule 13G) and is being filed by TCG Crossover Fund I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I, and together with TCG Crossover I, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is filed as Exhibit 1 to the Original Schedule 13G. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301.
    (c)Citizenship:

    TCG Crossover GP I is a limited liability company organized under the laws of the State of Delaware. TCG Crossover I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    91678A107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding comments.
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding comments.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding comments.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding comments.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding comments.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding comments.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TCG Crossover GP I, LLC
     
    Signature:/s/ Craig Skaling
    Name/Title:Authorized Signatory
    Date:11/14/2025
     
    TCG Crossover Fund I, L.P.
     
    Signature:/s/ Craig Skaling
    Name/Title:Authorized Signatory
    Date:11/14/2025
     
    Chen Yu
     
    Signature:/s/ Craig Skaling
    Name/Title:By POA as Attorney-in-Fact
    Date:11/14/2025
    Get the next $UPB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPB

    DatePrice TargetRatingAnalyst
    11/18/2025$40.00Outperform
    Evercore ISI
    10/14/2025$47.00Buy
    Truist
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    More analyst ratings

    $UPB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.

    SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

    11/14/25 4:27:07 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.

    SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

    11/14/25 4:05:34 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Upstream Bio Inc.

    S-3ASR - Upstream Bio, Inc. (0002022626) (Filer)

    11/5/25 7:37:28 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Upstream Bio with a new price target

    Evercore ISI initiated coverage of Upstream Bio with a rating of Outperform and set a new price target of $40.00

    11/18/25 8:28:41 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Upstream Bio with a new price target

    Truist initiated coverage of Upstream Bio with a rating of Buy and set a new price target of $47.00

    10/14/25 8:54:39 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Upstream Bio with a new price target

    Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

    11/5/24 6:29:20 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

    – Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks – – On-track to report top-line results from VALIANT Phase 2 trial in severe asthma in the first quarter of 2026 – – Enrollment ongoing in VENTURE Phase 2 trial in COPD; first patient dosed in July – WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for th

    11/5/25 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Participate in Upcoming November Investor Conferences

    WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium, New York, NYThursday, November 6, 2025, Panel - 8:10 a.m. ETStifel 2025 Healthcare Conference, New York, NYTuesday, November 11, 2025, Presentation - 9:20 a.m. ET TD Cowen Immunology and Inflammation Summit, VirtualWednesday, November 12, 2025, Fireside Chat - 10:30 a.m. ET

    10/31/25 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

    – Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – WALTHAM, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing verekitug

    9/30/25 4:15:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:19:30 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:17:52 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:05:04 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Renaud Ronald C Jr

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    6/12/25 4:17:33 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ruddy Marcella K.

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    6/12/25 4:17:30 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chimovits Erez

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    6/12/25 4:17:31 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Financials

    Live finance-specific insights

    View All

    Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    – In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

    9/2/25 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

    9/1/25 5:00:00 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Leadership Updates

    Live Leadership Updates

    View All

    Upstream Bio Appoints Stacy Price as Chief Technology Officer

    WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

    5/20/25 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Appoints Allison Ambrose as General Counsel

    WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

    12/17/24 8:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    11/7/24 9:24:55 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Upstream Bio Inc.

    SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

    10/22/24 4:06:27 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    10/18/24 6:10:56 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care